# OnCo record nct05669430 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05669430/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05669430", "NCT05669430" ;
  schema:name "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer, run by GV20 Therapeutics, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05669430/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05669430> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-03-23" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/gv20-therapeutics/> .